Overview

TMAB Therapeutics is developing first-in-class multi-specific antibodies designed to enhance immune activation while inhibiting angiogenesis within the solid tumor microenvironment. By simultaneously targeting CD5L and EGLF6, TMAB Therapeutics aims to overcome adaptive resistance to anti-VEGF and anti-PD1 therapies, offering a novel treatment approach for non-small cell lung cancer, microsatellite-stable colorectal cancer, and high-grade serous epithelial ovarian cancer.